Please login to the form below

Not currently logged in
Email:
Password:

Tudorza

This page shows the latest Tudorza news and features for those working in and with pharma, biotech and healthcare.

Circassia seeks shift to AIM after failing LSE criteria

Circassia seeks shift to AIM after failing LSE criteria

AZ’s booked sales for Tudorza fell more than 50% to $18m in the third quarter. ... The agreement between Circassia and AZ also includes a deferred Tudorza option payment of $20m payable upon approval of Duaklir, plus a deferred consideration of $100m.

Latest news

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    If Circassia sublicenses the rights to Tudorza in the US, it will pay a further $80m. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir (phase III) in COPD.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics